DiaMedica Therapeutics Statistics
Total Valuation
DMAC has a market cap or net worth of $334.34 million. The enterprise value is $283.22 million.
Important Dates
The last earnings date was Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DMAC has 53.88 million shares outstanding. The number of shares has increased by 19.44% in one year.
| Current Share Class | 53.88M |
| Shares Outstanding | 53.88M |
| Shares Change (YoY) | +19.44% |
| Shares Change (QoQ) | +2.63% |
| Owned by Insiders (%) | 47.24% |
| Owned by Institutions (%) | 24.50% |
| Float | 28.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.44 |
| P/TBV Ratio | 7.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.11, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.11 |
| Quick Ratio | 8.98 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -86.47% and return on invested capital (ROIC) is -56.19%.
| Return on Equity (ROE) | -86.47% |
| Return on Assets (ROA) | -49.96% |
| Return on Invested Capital (ROIC) | -56.19% |
| Return on Capital Employed (ROCE) | -77.61% |
| Weighted Average Cost of Capital (WACC) | 9.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.00M |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DMAC has paid $29,000 in taxes.
| Income Tax | 29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +59.85% in the last 52 weeks. The beta is 0.99, so DMAC's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +59.85% |
| 50-Day Moving Average | 6.82 |
| 200-Day Moving Average | 7.08 |
| Relative Strength Index (RSI) | 43.84 |
| Average Volume (20 Days) | 160,096 |
Short Selling Information
The latest short interest is 4.77 million, so 8.86% of the outstanding shares have been sold short.
| Short Interest | 4.77M |
| Short Previous Month | 4.59M |
| Short % of Shares Out | 8.86% |
| Short % of Float | 16.79% |
| Short Ratio (days to cover) | 20.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.74M |
| Pretax Income | -35.07M |
| Net Income | -35.10M |
| EBITDA | -36.69M |
| EBIT | -36.74M |
| Earnings Per Share (EPS) | -$0.71 |
Full Income StatementBalance Sheet
The company has $51.33 million in cash and $212,000 in debt, with a net cash position of $51.12 million or $0.95 per share.
| Cash & Cash Equivalents | 51.33M |
| Total Debt | 212,000 |
| Net Cash | 51.12M |
| Net Cash Per Share | $0.95 |
| Equity (Book Value) | 47.24M |
| Book Value Per Share | 0.88 |
| Working Capital | 46.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.00 million and capital expenditures -$36,000, giving a free cash flow of -$31.03 million.
| Operating Cash Flow | -31.00M |
| Capital Expenditures | -36,000 |
| Depreciation & Amortization | 43,000 |
| Net Borrowing | -10,000 |
| Free Cash Flow | -31.03M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.44% |
| Shareholder Yield | -19.44% |
| Earnings Yield | -10.50% |
| FCF Yield | -9.28% |
Analyst Forecast
The average price target for DMAC is $15.50, which is 149.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 149.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 15, 2018. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
